An R&D company focused on delivering innovative oncology and rare disease products to patients

Latest News
Jan 8, 2020

Positive Results from MTD201-102 Study Support Subcutaneous Route for Long-Acting Octreotide Product

Dec 5, 2019

Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer

Oct 28, 2019

Midatech Pharma PLC Announces Closing of US$3.0 Million Registered Direct Offering

Oct 24, 2019

Midatech's MTX110 Receives Orphan Designation for DIPG

Midatech Science
  Read More